Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Thursday, February 10, 2022

Information

Tags:

Hemoglobinopathy, Heart failure, GLOBE, Fireside, PDE9, Nasdaq, Heart failure with preserved ejection fraction, Sickle cell disease, Patient, Lists of diseases, Imara, Thalassemia, Conference, Therapy, Pharmaceutical industry, NFE2L2

Organisation:

IMARA, INC.

Summary

Key Points:

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m.
ET.
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases.
Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2related factor 2, or Nrf2.

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.

A replay of the webcast will be archived on the “Events and Presentations” section of Imara’s website.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment in Phase 2b clinical trials for sickle cell disease and beta-thalassemia. Imara expects to initiate a Phase 2 clinical trial of tovinontrine in heart failure with preserved ejection fraction (HFpEF) in the second quarter of 2022. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
[email protected]

Investor Contact:
Michael Gray
617-835-4061
[email protected]